मूलभूत आँकड़े
| CIK | 1810182 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ALX Oncology Holdings Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2025 |
Exhibit 99.1 ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-dr |
|
| June 12, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO |
|
| May 8, 2025 |
Separation Agreement and Release between the Registrant and Jaume Pons, Ph.D. Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Rel |
|
| May 8, 2025 |
Confirmatory Offer Letter between the Registrant and Alan Sandler, M.D. Exhibit 10.2 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. November 10, 2024 Alan Sandler, M.D. Via Email Re: Offer of Employment Dear Alan: I am please |
|
| May 8, 2025 |
Exhibit 99.1 ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update – Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025 – IND clearance received from U.S. FDA for novel EGFR-targeted a |
|
| May 8, 2025 |
Outside Director Compensation Policy. Exhibit 10.3 ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated effective as of January 16, 2025 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful t |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 23, 2025 |
CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 6, 2025 |
List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware |
|
| March 6, 2025 |
Confirmatory Offer Letter between the Registrant and Harish Shantharam. Exhibit 10.8 January 17, 2025 Harish Shantharam Via Email Re: Offer of Employment Dear Harish: I am pleased to offer you a position with ALX Oncology Holdings Inc. (the “Company”) in accordance with the terms of this Offer of Employment letter agreement (the “Agreement”). 1. Title; Position; Location. If you accept this offer of employment, you will serve as the Company’s Chief Financial Officer ( |
|
| March 6, 2025 |
Confirmatory Offer Letter between the Registrant and Alan Sandler, M.D. Exhibit 10.11 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items October 11, 2024 Alan Sandler, M.D. Via Email Re: Offer of Employment Dear Alan: I am pleased |
|
| March 6, 2025 |
Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data demonstrating evorpacept in |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
Separation Agreement and Release between the Registrant and Peter García. Exhibit 10.14 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND MUTUAL RELEASE This Separation Agreement |
|
| March 6, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) ALX ONCOLOGY HOLDINGS INC. |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 6, 2025 |
Exhibit 19.1 ALX ONCOLOGY HOLDINGS INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (Adopted and approved June 25, 2020 and effective as of the Company’s initial public offering, as amended on March 14, 2023) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violati |
|
| March 6, 2025 |
Outside Director Compensation Policy. Exhibit 10.19 ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as most recently amended and restated effective as of January 16, 2025 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 14, 2025 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings, Inc. and further agree to the filing of this agreement as an exhibit |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| January 22, 2025 |
Exhibit 99.1 ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operations - Dr. Klencke is a se |
|
| January 17, 2025 |
2025 Inducement Equity Incentive Plan and forms of agreement thereunder. Exhibit 10.1 ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Righ |
|
| January 17, 2025 |
As filed with the Securities and Exchange Commission on January 17, 2025 S-8 1 d865005ds8.htm S-8 As filed with the Securities and Exchange Commission on January 17, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 85-0642577 (State or other jurisdiction of incorpora |
|
| January 17, 2025 |
2025 Inducement Equity Incentive Plan and forms of agreement thereunder. Exhibit 4.3 ALX ONCOLOGY HOLDINGS INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Right |
|
| January 17, 2025 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $ |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 31, 2024 |
SC TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 00166B105 (CUSIP |
|
| December 2, 2024 |
Exhibit (a)(1)(D) ALX ONCOLOGY HOLDINGS INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS ELECTION FORM THE OFFER EXPIRES AT 9:00 P.M., PACIFIC TIME, ON DECEMBER 30, 2024, UNLESS THE OFFER IS EXTENDED Terms used in this Election Form, including the Election Terms & Conditions and Election Instructions attached hereto, that are defined in the Offer to Exchange have the |
|
| December 2, 2024 |
Form of Eligible Option Schedule. Exhibit (a)(1)(C) Eligible Option Grant Schedule ALX Oncology Holdings Inc. ID: 85-642577 323 Allerton Avenue South San Francisco, California 94080 AS OF DECEMBER 2, 2024 [Name] Employee ID: [Number] [Address] ELIGIBLE OPTION GRANT NEW OPTION GRANT Grant Date Grant Number Exercise Price Per Share Type of Eligible Option Grant (ISO / NSO) Number of Vested Shares Subject to Eligible Option Grant Thr |
|
| December 2, 2024 |
Exhibit (a)(1)(E) Form of Confirmation to Eligible Employees ALX Oncology Holdings Inc. |
|
| December 2, 2024 |
Exhibit 107 Calculation of Filling Fee Tables Schedule TO (Form Type) ALX Oncology Holdings Inc. |
|
| December 2, 2024 |
Exhibit (a)(1)(F) Form of Reminder Email The ALX Oncology Holdings Inc. (“ALX”) offer to exchange certain outstanding stock options for new stock options (referred to as the “Offer”) currently is still open. Please note that the Offer will expire at 9:00 p.m., Pacific Time, on December 30, 2024, unless we extend the Offer. The Offer deadline will be strictly enforced, so we encourage you to give y |
|
| December 2, 2024 |
Form of Notice Email Announcing Final Offer Terms. Exhibit (a)(1)(G) Form of Notice Email Announcing Final Offer Terms To: Eligible Employees From: Jason Lettmann, Chief Executive Officer, ALX Oncology Holdings Inc. |
|
| December 2, 2024 |
Offer to Exchange Certain Outstanding Stock Options for New Stock Options, dated December 2, 2024. Exhibit (a)(1)(A) ALX ONCOLOGY HOLDINGS INC. OFFER TO EXCHANGE CERTAIN OUTSTANDING STOCK OPTIONS FOR NEW STOCK OPTIONS This document constitutes part of the prospectus relating to the securities that have been registered under the Securities Act of 1933, as amended. The prospectus relates to the ALX Oncology Holdings Inc. Amended and Restated 2020 Equity Incentive Plan. December 2, 2024 ALX ONCOLO |
|
| December 2, 2024 |
Exhibit (a)(1)(B) EMAIL TO ALL ELIGIBLE EMPLOYEES From: optionexchange@alxoncology. |
|
| December 2, 2024 |
Form of Expiration Notice Email. Exhibit (a)(1)(H) Form of Notice to Eligible Employees Regarding Expiration of Offering Period To: Eligible Employees From: optionexchange@alxoncology. |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, $0.001 par value (Title of Class of Securities) 00166B105 (CUSIP Number of Class of Securities’ |
|
| November 14, 2024 |
ALXO / ALX Oncology Holdings Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-alxo093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 14, 2024 |
SC 13G/A 1 ea022116103-13ga1viv9alxon.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX Oncology Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event whi |
|
| November 14, 2024 |
ALXO / ALX Oncology Holdings Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss4113341sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00166B105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stat |
|
| November 14, 2024 |
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Exhibit 99.1 ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development SOUTH SAN FRANCISCO, Calif., November 14, 2024 - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune s |
|
| November 14, 2024 |
EX-99.1 2 ea022116103ex99-1alxon.htm JOINT FILING STATEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A shall be filed on behalf of each of the undersigned without the necessity of filing additional joint f |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON |
|
| November 7, 2024 |
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 7, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today report |
|
| November 7, 2024 |
Separation Agreement and Release between the Registrant and Sophia Randolph, M.D., Ph.D. Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. ALX ONCOLOGY HOLDINGS INC. SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Rel |
|
| October 10, 2024 |
ALXO / ALX Oncology Holdings Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00166B105 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 22, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. and further agree to the filing |
|
| August 22, 2024 |
ALXO / ALX Oncology Holdings Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 13, 2024 |
ALXO / ALX Oncology Holdings Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 00166B105 (CUSIP Number) AUGUST 6, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2024 |
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., August 8, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 6, 2024 |
Exhibit 99.1 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors ▪ Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development – ▪ Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company’s clinical program advances – SOUTH SAN FRANCISCO, Calif., August 6, 2024 (GLOBE NEWSWIRE) - |
|
| June 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 9, 2024 |
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., May 9, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 8, 2024 |
As filed with the Securities and Exchange Commission on March 7, 2024 As filed with the Securities and Exchange Commission on March 7, 2024 Registration No. |
|
| March 8, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0 |
|
| March 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO |
|
| March 7, 2024 |
Exhibit 97.1 ALX ONCOLOGY HOLDINGS INC. COMPENSATION RECOVERY POLICY As adopted on July 25, 2023 ALX Oncology Holdings Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”) pursuant to approval by the Compensation Committee (the “Committee”) of the Company’s B |
|
| March 7, 2024 |
Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., March 7, 2024 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth q |
|
| March 7, 2024 |
List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo International Holdings Limited Malta |
|
| March 7, 2024 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio |
|
| February 14, 2024 |
ALXO / ALX Oncology Holdings Inc. / LSV Associates, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm246244d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Travis Boettner Lightstone Ventures 500 Boylston St. Suite 1380 Boston, |
|
| February 14, 2024 |
EX-99.1 2 tm245846d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ALX Onc |
|
| February 14, 2024 |
ALXO / ALX Oncology Holdings Inc. / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245846d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2024 |
EX-99.A 2 ss30005514ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Amendment No. 1 to the Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of |
|
| February 14, 2024 |
ALXO / ALX Oncology Holdings Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 26, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of December 22, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the |
|
| December 20, 2023 |
ALXO / ALX Oncology Holdings Inc. / LSV Associates, LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Travis Boettner Lightstone Ventures 500 Boylston St. Suite 1380 Boston, MA 02116 (617) 933-3770 (Name, Address an |
|
| November 13, 2023 |
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update Exhibit 99.1 ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update SOUTH SAN FRANCISCO, Calif., November 13, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the third quarter ended |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 13, 2023 |
Amendment No. 1 to the Sales Agreement with Cantor and Credit Suisse, dated August 25, 2023. Exhibit 10.1 [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that the registrant treats as private or confidential. ALX ONCOLOGY HOLDINGS INC. AMENDMENT NO. 1 TO THE SALES AGREEMENT August 25, 2023 Cantor Fitzgerald & Co. 110 E 59th Steet, 6th F |
|
| October 16, 2023 |
EX-99.1 2 tm2328366d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ALX On |
|
| October 16, 2023 |
ALXO / Alx Oncology Holdings Inc / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) October 4, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| October 13, 2023 |
ALXO / Alx Oncology Holdings Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALX Oncology Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) October 3, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| October 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 13, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC Cormorant Asset Management, LP and Bihua |
|
| October 6, 2023 |
EX-4.1 Exhibit 4.1 ALX ONCOLOGY HOLDINGS INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: [], 2023 ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its permitted registered |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 6, 2023 |
EX-1.1 Exhibit 1.1 7,370,690 Shares and Pre-Funded Warrants to Purchase 1,250,000 Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT October 4, 2023 PIPER SANDLER & CO. CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o PIPER SANDLER & CO. 1251 Avenue of the Americas, 6th Floor New York, New York 10020 c/o CANTOR FITZGERALD & CO. 110 E. 59th St., 6th Floor New York, N |
|
| October 6, 2023 |
ALX Oncology Announces Pricing of Public Offering EX-99.1 Exhibit 99.1 ALX Oncology Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., October 5, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the pricing of its previously announced underwritten public offering of comm |
|
| October 6, 2023 |
7,370,690 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263863 Prospectus Supplement (To Prospectus Dated May 25, 2022) 7,370,690 Shares of Common Stock Pre-Funded Warrants to Purchase 1,250,000 Shares of Common Stock We are offering 7,370,690 shares of our common stock, par value $0.001 per share (common stock) and, in lieu of common stock to certain investors, pre-funded wa |
|
| October 4, 2023 |
Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263863 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| October 4, 2023 |
Exhibit 99.1 ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer — Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for |
|
| September 8, 2023 |
18,446,936 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-274314 PROSPECTUS 18,446,936 Shares of Common Stock This prospectus relates to the proposed resale or other disposition from time to time of up to 18,446,936 shares of our common stock, par value $0.001 per share by the selling stockholders identified in this prospectus, including their transferees, pledgees, donees or other s |
|
| September 7, 2023 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| September 6, 2023 |
Confirmatory Employment Letter between the Registrant and Jason Lettmann. EX-10.1 Exhibit 10.1 323 Allerton Avenue South San Francisco, California Phone: (650) 466-7125 September 5, 2023 Jason Lettmann Via Email Re: Offer of Employment Dear Jason: I am pleased to offer you a position with ALX Oncology Holdings Inc. (the “Company”) in accordance with the terms of this Offer of Employment letter agreement (the “Agreement”). 1. Title; Position; Location. If you accept this |
|
| September 6, 2023 |
Confirmatory Employment Letter between the Registrant and Jaume Pons, Ph.D. EX-10.2 Exhibit 10.2 323 Allerton Avenue South San Francisco, California Phone: (650) 466-7125 September 5, 2023 Jaume Pons, Ph.D. Via Email Re: Confirmatory Employment Letter Dear Jaume: This confirmatory employment letter agreement (the “Agreement”) is entered into between Jaume Pons (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of September 6, 2023 (the “Effective |
|
| September 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 6, 2023 |
EX-99.1 Exhibit 99.1 ALX Oncology Realigns Executive Leadership Team - Jason Lettmann appointed as Chief Executive Officer - Dr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., September 6, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune c |
|
| September 1, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) ALX Oncology Holdings Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees |
|
| September 1, 2023 |
As filed with the Securities and Exchange Commission on September 1, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on September 1, 2023 Registration No. |
|
| August 25, 2023 |
Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration Number 333-263863 Supplement dated August 25, 2023 To Prospectus Supplement dated May 25, 2022 (To Prospectus dated May 25, 2022) Up to $150,000,000 Common Stock This supplement, or Supplement, updates, amends and supplements the prospectus supplement, dated May 25, 2022, or Prospectus Supplement, relating to the offer and sale of shares of common stock, par value $0. |
|
| August 10, 2023 |
Second Amendment to Loan and Security Agreement, dated as of May 31, 2023. Exhibit 10.1 [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this document, marked by brackets, has been omitted because it is both not material and is the type of information that the registrant treats as private or confidential. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entere |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG |
|
| August 10, 2023 |
Exhibit 99.1 ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 immune che |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 20, 2023 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.1 ALX ONCOLOGY HOLDINGS INC. AMENDED AND RESTATED BYLAWS (initially adopted on April 1, 2020) (as amended effective on June 17, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOC |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 11, 2023 |
Exhibit 99.1 ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fir |
|
| May 11, 2023 |
Outside Director Compensation Policy. ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as amended and restated effective as of March 14, 2023 (the “Restatement Date”)) ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful tool to attract, retain and re |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 9, 2023 |
Consent and First Amendment to Loan and Security Agreement, dated as of December 22, 2022. Exhibit 10.1.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. CONSENT AND FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT |
|
| March 9, 2023 |
List of subsidiaries of Registrant. SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo International Holdings Limited Malta |
|
| March 9, 2023 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0 |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO |
|
| March 9, 2023 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio |
|
| March 9, 2023 |
Power of Attorney (contained on signature page hereto). S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., March 9, 2023 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, toda |
|
| February 14, 2023 |
ALXO / ALX Oncology Holdings Inc / ORBIMED ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 ss1758552sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2023 |
EX-99.A 2 ss1758552ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Common Stock, $0.001 par value per share, of ALX Oncology Holdings Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 29, 2022 |
ALX Oncology Appoints Scott Garland to its Board of Directors Exhibit 99.1 ALX Oncology Appoints Scott Garland to its Board of Directors SOUTH SAN FRANCISCO, Calif., November 29, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Scott Garland to its Board of Directors (the ?Board?) effectiv |
|
| November 8, 2022 |
Exhibit 99.1 ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 8, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ON |
|
| October 31, 2022 |
Exhibit 10.1 Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registrant may request confidential treatment of omitted items. [***] = Pursuant to Item 601(b)(10) of Regulation S-K, certain information contained in this |
|
| October 31, 2022 |
Exhibit 99.1 ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Expects to extend cash runway to mid-2025 SOUTH SAN FRANCISCO, Calif., October 31, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block t |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 8, 2022 |
Exhibit 99.1 ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., August 8, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the s |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLOG |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 27, 2022 |
As filed with the U.S. Securities and Exchange Commission on May 27, 2022 As filed with the U.S. Securities and Exchange Commission on May 27, 2022 Registration No. 333-258812 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT Under The Securities Act of 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 85-0642577 (State or other jurisdict |
|
| May 24, 2022 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| May 13, 2022 |
As filed with the Securities and Exchange Commission on May 13, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 13, 2022 Registration No. |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2022 |
Exhibit 99.1 ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., May 9, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39386 ALX ONCOLO |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 12, 2022 |
ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors Exhibit 99.1 ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (th |
|
| March 25, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. |
|
| March 25, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-3 (Form Type) ALX Oncology Holdings Inc. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio |
|
| February 28, 2022 |
Confirmatory Offer Letter between the Registrant and Shelly Pinto. Exhibit 10.6 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 May 3, 2021 Shelly Pinto Via Email Re: Confirmatory Employment Letter Dear Shelly: This confirmatory employment letter agreement (the ?Agreement?) is entered into between Shelly Pinto (?you?) and ALX Oncology Holdings Inc. (the ?Company? or ?we?), effective as of May 3, 2021 (the ?Effective Date?), to confirm the t |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO |
|
| February 28, 2022 |
List of subsidiaries of Registrant. Exhibit 21.1 SUBSIDIARIES OF ALX ONCOLOGY HOLDINGS INC. Name of Subsidiary Jurisdiction of Incorporation or Organization ALX Oncology Limited Ireland ALX Oncology Incorporated Delaware Alexo Holding Limited Malta Alexo Therapeutics International Cayman Islands Sirpant Therapeutics Cayman Islands ScalmiBio, Inc. Delaware |
|
| February 28, 2022 |
Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0 |
|
| February 28, 2022 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| December 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commi |
|
| December 17, 2021 |
Exhibit 1.1 Execution Version ALX ONCOLOGY HOLDINGS INC. Shares of Common Stock (par value $0.001 per share) Sales Agreement December 17, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 Ladies and Gentlemen: ALX Oncology Holdings Inc., a Delaware corporation (the ?Company?), confirms its agreement (th |
|
| December 17, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-258812 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee (1) Common stock, par value $0. |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC. |
|
| November 12, 2021 |
Exhibit 99.1 ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights SOUTH SAN FRANCISCO, Calif., November 11, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter en |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 7, 2021 |
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Exhibit 99.1 ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio ? Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugates ? Expands ALX Oncology?s pipeline of drug candidates based on expertise in protein engineering and oncology SOUTH SAN F |
|
| October 7, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| September 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALX ONCOLOGY HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 00166B105 (CUSIP Number) August 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2021 |
Registration Statement on Form S-3 Table of Contents As filed with the Securities and Exchange Commission on August 13, 2021 Registration No. |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 12, 2021 |
Exhibit 99.1 ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., August 12, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Virginia Yee Logos Global Management LP One Letterman Drive, Building D, Suite D3-700 San Francisco, CA 94129 Tele |
|
| June 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commissio |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC. |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 17, 2021 |
Exhibit 99.1 ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., May 17, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 18, 2021 |
Exhibit 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Sectio |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39386 ALX ONCOLOGY HO |
|
| March 18, 2021 |
Exhibit 99.1 ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones BURLINGAME, Calif., March 18, 2021 - ALX Oncology Holdings Inc., (?ALX Oncology?) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial resul |
|
| March 18, 2021 |
As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| March 15, 2021 |
ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors EX-99.1 Exhibit 99.1 ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors BURLINGAME, Calif., March 15, 2021 (GLOBE NEWSWIRE) - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Sophia Randolph, M.D., Ph.D., to its |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction (Commission (IRS Employer o |
|
| December 23, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction (Commission (IRS Emp |
|
| December 11, 2020 |
424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-251171 and 333-251248 PROSPECTUS 2,380,000 Shares Common Stock We are offering 2,380,000 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “ALXO.” On December 9, 2020, the last reported sale price of our common stock on the Nasdaq Global Select Market was $81.73 p |
|
| December 10, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on December 9, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 85-0642577 (State or other jurisdiction of incorporation or orga |
|
| December 7, 2020 |
December 7, 2020 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 7, 2020 |
December 7, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| December 7, 2020 |
S-1 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on December 7, 2020 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| December 7, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [●] Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT [●], 2020 JEFFERIES LLC CREDIT SUISSE SECURITIES (USA) LLC PIPER SANDLER & CO. CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, New York 10010 c/o PIPER SANDLER & CO |
|
| November 24, 2020 |
Draft Registration Statement Table of Contents Index to Financial Statements Confidential Treatment Requested by ALX Oncology Holdings Inc. |
|
| November 12, 2020 |
Exhibit 99.1 ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights BURLINGAME, Calif., November 12, 2020 - ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the third quarter ended Septe |
|
| November 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC. |
|
| October 1, 2020 |
ALXO / ALX Oncology Holdings Inc. / venBio Global Strategic Fund II L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ALX ONCOLOGY HOLDINGS INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) David Pezeshki venBio Partners, LLC 1700 Owens Street, Suite 595, San Francisco, CA 94158 (415) 800-0800 (Name, Ad |
|
| August 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39386 ALX ONCOLOGY HOLDINGS INC. |
|
| August 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39386 85-0642577 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 27, 2020 |
Exhibit 99.1 ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Completed initial public offering of common stock on July 21, 2020, raising gross proceeds of $185.7 million Strengthened leadership team and expanded board of directors to support growth IND open for ALX148 in combination with azacitidine for first-line treatment of patients wi |
|
| August 26, 2020 |
ALXO / ALX Oncology Holdings Inc. / Logos Global Management LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ALX Oncology Holdings Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) Virginia Yee Logos Global Management LP One Letterman Drive, Building D, Suite D3-700 San Francisco, CA 94129 Telep |
|
| July 31, 2020 |
ALXO / ALX Oncology Holdings Inc. / LSV Associates, LLC - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| July 31, 2020 |
Agreement regarding filing of joint Schedule 13D EX-99.A Exhibit A JOINT FILING STATEMENT I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the Common Stock of ALX Oncology Holdings Inc. is filed on behalf of each of the undersigned. Date: July 30, 2020 Lightstone Ventures, L.P. Lightstone Ventures (A), L.P. By: LSV Associates, LLC Its: General Partner By: /s/ Travis Boettner |
|
| July 29, 2020 |
ALXO / ALX Oncology Holdings Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ALX Oncology Holdings Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 00166B105 (CUSIP Number) July 21, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| July 22, 2020 |
Exhibit 24 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Travis Boettner, the undersigned's true and lawful attorney-in-fact and agent to: (i) prepare, execute and file, for and on behalf of the undersigned, any and all documents and filings that are required or advisable to be made with the United States Securities and Exchange Commission, any |
|
| July 21, 2020 |
Amended and Restated Bylaws of the Registrant. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ALX ONCOLOGY HOLDINGS INC. (initially adopted on April 1, 2020) (as amended on June 25, 2020 and effective as of the closing of the corporation’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETI |
|
| July 21, 2020 |
Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALX ONCOLOGY HOLDINGS INC. ALX Oncology Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A. The name of the Corporation is ALX Oncology Holdings Inc. The Corporation was originally incorporated pursuant to the General Corporation La |
|
| July 21, 2020 |
EX-99.1 Exhibit 99.1 ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares BURLINGAME, Calif. – July 21, 2020 – ALX Oncology Holdings Inc., (Nasdaq:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the closing of its initial public offering of 9, |
|
| July 21, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2020 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-39386 85-0642577 (State or other jurisdiction of incorporation) (Commi |
|
| July 17, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-239490 PROSPECTUS 8,500,000 Shares Common Stock We are offering 8,500,000 shares of our common stock. This is our initial public offering of our common stock, and no public market currently exists for our common stock. The initial public offering price is $19.00 per share. Our common stock has been approved for listing o |
|
| July 17, 2020 |
S-8 As filed with the Securities and Exchange Commission on July 17, 2020 Registration No. |
|
| July 16, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on July 16, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 85-0642577 (State or other jurisdiction of incorporation or organiz |
|
| July 14, 2020 |
Company Acceleration Request July 14, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| July 14, 2020 |
Underwriter Acceleration Request July 14, 2020 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| July 13, 2020 |
2020 Employee Stock Purchase Plan. Exhibit 10.3 ALX ONCOLOGY HOLDINGS INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock purchase plan? under Co |
|
| July 13, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ALX ONCOLOGY HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 85-0642577 (State of incorporation or organization) (I.R.S. Employer Identification No.) 866 Malcol |
|
| July 13, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALX ONCOLOGY HOLDINGS INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALX ONCOLOGY HOLDINGS INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) ALX Oncology Holdings Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation |
|
| July 13, 2020 |
Executive Incentive Compensation Plan. EX-10.9 Exhibit 10.9 ALX ONCOLOGY HOLDINGS INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. (a) “Actual Award” means as to any Performance Period, the actual award (if any |
|
| July 13, 2020 |
Form of Change in Control and Severance Agreement. EX-10.11 Exhibit 10.11 ALX ONCOLOGY HOLDINGS INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), and (“Executive”), effective as of the Effective Date, as defined in Section 8 below. This Agreement provides certain protections to Executive in connec |
|
| July 13, 2020 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [●] Shares ALX Oncology Holdings Inc. UNDERWRITING AGREEMENT July [●], 2020 JEFFERIES LLC CREDIT SUISSE SECURITIES (USA) LLC PIPER SANDLER & CO. CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, New York 10010 c/o PIPER SANDLER |
|
| July 13, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALX ONCOLOGY HOLDINGS INC. ALX Oncology Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A. The name of the Corporation is ALX Oncology Holdings Inc. The Corporation was originally incorporated pursuant to the General Corporation La |
|
| July 13, 2020 |
Outside Director Compensation Policy. EX-10.10 Exhibit 10.10 ALX ONCOLOGY HOLDINGS INC. OUTSIDE DIRECTOR COMPENSATION POLICY ALX Oncology Holdings Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents a powerful tool to attract, retain and reward Directors who are not employees of the Company (“Outsi |
|
| July 13, 2020 |
Confirmatory Offer Letter between the Registrant and Sophia Randolph, M.D., Ph.D. EX-10.8 Exhibit 10.8 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 July 9, 2020 Sophia Randolph, M.D., Ph.D. Via Email Re: Confirmatory Employment Letter Dear Sophia: This confirmatory employment letter agreement (the “Agreement”) is entered into between Sophia Randolph (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of July 9, 2020 (the “Effec |
|
| July 13, 2020 |
Confirmatory Offer Letter between the Registrant and Nathan Caffo, effective as of July 9, 2020. EX-10.5 Exhibit 10.5 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 July 9, 2020 Nathan Caffo Via Email Re: Confirmatory Employment Letter Dear Nathan: This confirmatory employment letter agreement (the “Agreement”) is entered into between Nathan Caffo (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of July 9, 2020 (the “Effective Date”), to con |
|
| July 13, 2020 |
Amended and Restated 2020 Equity Incentive Plan and forms of agreements thereunder. EX-10.2 Exhibit 10.2 ALX ONCOLOGY HOLDINGS INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits th |
|
| July 13, 2020 |
Confirmatory Offer Letter between the Registrant and Jaume Pons, Ph.D. EX-10.4 Exhibit 10.4 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 July 9, 2020 Jaume Pons, Ph.D. Via Email Re: Confirmatory Employment Letter Dear Jaume: This confirmatory employment letter agreement (the “Agreement”) is entered into between Jaume Pons (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of July 9, 2020 (the “Effective Date”), to c |
|
| July 13, 2020 |
Confirmatory Offer Letter between the Registrant and Steffen Pietzke. EX-10.7 Exhibit 10.7 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 July 9, 2020 Steffen Pietzke Via Email Re: Confirmatory Employment Letter Dear Steffen: This confirmatory employment letter agreement (the “Agreement”) is entered into between Steffen Pietzke (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of July 9, 2020 (the “Effective Date”), |
|
| July 13, 2020 |
Confirmatory Offer Letter between the Registrant and Peter García. EX-10.6 Exhibit 10.6 866 Malcolm Road, Suite 100 Burlingame, CA 94010 Phone: (650) 466-7125 July 9, 2020 Peter Garcia Via Email Re: Confirmatory Employment Letter Dear Peter: This confirmatory employment letter agreement (the “Agreement”) is entered into between Peter Garcia (“you”) and ALX Oncology Holdings Inc. (the “Company” or “we”), effective as of July 9, 2020 (the “Effective Date”), to conf |
|
| July 13, 2020 |
Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on July 13, 2020. Registration No. 333-239490 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 ALX ONCOLOGY HOLDINGS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 85- |
|
| July 2, 2020 |
CORRESP Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 O: 650. |
|
| June 26, 2020 |
Form of Amended and Restated Warrant to Purchase Stock. EX-4.3 Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ACT), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND |
|
| June 26, 2020 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on June 26, 2020. |
|
| June 26, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALX ONCOLOGY HOLDINGS INC. ALX Oncology Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A. The name of the Corporation is ALX Oncology Holdings Inc. The Corporation was originally incorporated pursuant to the General Corporation La |
|
| June 26, 2020 |
EX-10.1 Exhibit 10.1 ALX ONCOLOGY HOLDINGS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [, 20] and is between ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve a |
|
| June 26, 2020 |
EX-10.12 Exhibit 10.12 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***]. EXCLUSIVE (EQUITY) AGREEMENT This Exclusive (Equity) Agreement (“Agreement”) betwee |
|
| June 26, 2020 |
Bylaws of the Registrant, as currently in effect. EX-3.3 Exhibit 3.3 BYLAWS OF ALX ONCOLOGY HOLDINGS INC. Adopted as of April 1, 2020 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 1 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 2 1.9 Stockholder Action by Written Consent Without a Meeting 3 1. |
|
| June 26, 2020 |
Specimen common stock certificate of the Registrant. EX-4.2 Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $.001 ALX ONCOLOGY HOLDINGS INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK Shares THIS CERTIFIES is the owner of SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 00166B 10 5 Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** 000000**Shares****000000**Shares |
|
| June 26, 2020 |
EX-10.15 Exhibit 10.15 RESEARCH AND DEVELOPMENT SERVICES AGREEMENT This research and development services agreement (the “Agreement”) is made effective as of July 1, 2020 (the “Effective Date”) by and between ALX Oncology Holdings Inc., a Delaware corporation (“ALX”) having an address at 866 Malcolm Road, Suite 100, Burlingame, California 94010, and Tallic Therapeutics, Inc. (f/k/a Tollnine, Inc.) |
